GlobeNewswire

Eurocastle Releases First Half 2020 Financial Results

Share

Contact:                                                                                                                                                                                            
Oak Fund Services (Guernsey) Limited
Company Administrator
Attn:  Mark Woodall
Tel:  +44 1481 723450                                                                                          

Eurocastle Releases First Half 2020 Financial Results

­
Guernsey, 7 August 2020 – Eurocastle Investment Limited (Euronext Amsterdam: ECT) today has released its financial report for the six months ended 30 June 2020.

  • Adjusted Net Asset Value (“NAV”) of €13.4 million1, or €7.26 per share2 up €0.48 per share vs. €6.78 per share at Q1 2020 (down €1.06 per share vs. €8.32 per share at Q4 2019) due to:
    1. Valuation movements:
      • €0.19 per share increase (4%) in Q2 2020 (€1.43 per share decrease in H1 2020) on the remaining three real estate fund investments
      • €0.05 per share increase (9%) in Q2 2020 (€0.03 per share decrease in H1 2020) on the remaining three NPL and other loan interests
    2. Positive reserve and legacy movements of €0.24 per share in Q2 2020 (€0.40 per share increase in H1 2020)

The table below summarises the movements in the Adjusted NAV for the quarter:

Q1 2020 Q2 Cash Movement Q2 FV MovementQ2 2020
€ million€ per share€ million€ per share€ million€ per share€ million€ per share
Real Estate Funds9.95.320.10.060.40.1910.35.57
Italian NPLs & Other Loans1.00.56(0.0)(0.01)0.10.051.10.60
Net Corporate Cash31.60.900.10.050.50.242.01.09
Adjusted NAV12.56.78--1.000.4813.47.26

The Company’s current assets comprise:

  • Interests in two real estate redevelopment funds where construction is fully completed. The units are in the process of being sold but encountering delays due to the coronavirus outbreak. Both developments offer luxury residential apartments with high specification furnishings in Rome.
  • Interest in a public fund which is in the process of being liquidated and the assets of which predominantly comprise cash.
  • Residual minority interests in three predominantly secured NPL & Other Loan pools.


H1 2020 INVESTMENT REALISATIONS AND MARKET OUTLOOK

COVID-19 has had an extraordinary impact across all sectors of the economy. The Company’s move to realise the majority of its assets in Q4 2019 and its prudent management of cash reserves have left the Company well placed to maximize the value of its remaining assets from a position of strength. This has been evidenced in the performance of its remaining assets where in the first half of 2020 the Company achieved the following milestones:

  • Closed or collected offers under contract on 25% of remaining real estate units available for sale as at 1 January 2020 in Real Estate Fund Investment II and 23% in Real Estate Fund Investment V.  Assuming that all these offers close, only 19% of units in one building in Real Estate Fund Investment II (with the second building already fully sold) and 48% of the units in Real Estate Fund Investment V will remain to be disposed of. Since the end of the lockdown phase in Italy in May 2020 there has been renewed interest in the apartments due to pent-up demand in the market for quality, semi-central residential real estate in Rome. 
  • Following the disposal of all of the assets in Real Estate Fund Investment I in 2019, the Company received €1.0 million, or 41% of its Q4 2019 NAV, in the first half of 2020. The fund is in the process of being liquidated and its assets predominantly comprise of cash. The fund is currently trading at a c.10% discount to its last published NAV.
  • The residual NPL & Other Loan interests, which are predominantly secured, have continued to generate cash proceeds, in spite of the turmoil created by COVID-19. In the first 6 months of the year the pools generated and distributed €0.1 million, or ~6% of the Q4 2019 NAV.
  • Following favourable outcomes on certain potential liabilities along with various cost savings, the Company was able to generate a total net reduction on reserves of €0.6 million in the first half of the year. Since implementation of the Realisation Plan in 2019, the Company has generated total savings of €0.8 million against these reserves. Part of these savings are as a result of the Board of Directors agreeing to reduce their annual remuneration from €0.2 million to €0.1 million.
  • The cash received in the first half of the year across the Company’s investments, along with the current cash set aside for reserves as part of the Realisation Plan, leave the Company well capitalised and in a strong position to weather the uncertainty that COVID-19 has created.


§ 

Income Statement for the Six and Three Months ended 30 June 2020 (Unaudited)H1 2020Q2 2020
€ Thousands€ Thousands
Portfolio Returns
Italian NPLs & Other Loans(66)91
Real Estate Funds(2,975)351
Fair value movement on Italian investments(3,041)442
Fair value movements on residual Legacy entities207216
Other income1616
Loss on foreign currency translation -(3)
Total (loss) / income(2,818)671
Operating Expenses
Interest expense4217
  Manager base and incentive fees21126
  Remaining operating expenses1,047586
Other Operating expenses1,068712
Total expenses1,110729
Loss for the period(3,928)(58)
€ per share(2.12)(0.03)



Balance Sheet and Adjusted NAV Reconciliation as at 30 June 2020 (Unaudited)

Italian Investments
€ Thousands


Corporate
€ Thousands
Total
€ Thousands
Assets
Cash and cash equivalents-20,66320,663
Other assets-4747
Investments:
  Italian NPLs & Other Loans1,120-1,120
  Real Estate Funds10,315-10,315
Total assets11,34520,71032,145
Liabilities
Trade and other payables-1,5471,547
Manager base and incentive fees-138138
Total liabilities-1,6851,685
IFRS NAV11,43519,02530,460
Additional Reserves3-(17,016)(17,016)
Adjusted NAV 11,4352,00913,444
Adjusted NAV (€ per share)46.181.087.26

PDMR UPDATE

The Company issued 1,000 ordinary shares to each of its three independent directors as part of their in-place compensation arrangements. By reference to its obligations under Article 19 of EU Regulation 596/2014, the Company is making public the following details of those dealings in its shares by persons discharging managerial responsibilities:

Name of the PDMRFinancial InstrumentNature of TransactionDate and place of transactionVolume and price of transaction
Dr. Simon John ThorntonOrdinary SharesAcquisition for nil consideration as part of compensation arrangements6 August 2020, Guernsey1,000 shares
Nil consideration
Mrs. Claire Elizabeth Ann WhittetOrdinary SharesAcquisition for nil consideration as part of compensation arrangements6 August 2020, Guernsey1,000 shares
Nil consideration
Mr. Jason de Beauvoir Sherwill (via Forein Limited, Closely Associated Person)Ordinary SharesAcquisition for nil consideration as part of compensation arrangements6 August 2020, Guernsey1,000 shares
Nil consideration

As a consequence of the above:

  • The total number of Ordinary Shares of the Company in issue is 1,854,535; and
  • The total number of voting rights exercisable by holders of Ordinary Shares of the Company is 1,854,535.

NOTICE:

This announcement contains inside information for the purposes of the Market Abuse Regulation 596/2014.

ADDITIONAL INFORMATION

For investment portfolio information, please refer to the Company’s most recent Financial Report, which is available on the Company’s website (www.eurocastleinv.com).

ABOUT EUROCASTLE

Eurocastle Investment Limited (“Eurocastle” or the “Company”) is a publicly traded closed-ended investment company, focused on Italian performing and non-performing loans, Italian loan servicing platforms and other real estate related assets in Italy. On 18 November 2019, the Company announced a plan to realise the majority of its assets with the aim of accelerating the return of value to shareholders. The Company will not currently seek material new investments from the proceeds of the realisation but, will continue to support its existing investments to the extent required in order to optimise returns and distribute cash to shareholders when available (the “Realisation Plan”). For more information regarding Eurocastle Investment Limited and to be added to our email distribution list, please visit www.eurocastleinv.com.

FORWARD LOOKING STATEMENTS

This release contains statements that constitute forward-looking statements. Such forward-looking statements may relate to, among other things, future commitments to sell real estate and achievement of disposal targets, availability of investment and divestment opportunities, timing or certainty of completion of acquisitions and disposals, the operating performance of our investments and financing needs. Forward-looking statements are generally identifiable by use of forward-looking terminology such as “may”, “will”, “should”, “potential”, “intend”, “expect”, “endeavor”, “seek”, “anticipate”, “estimate”, “overestimate”, “underestimate”, “believe”, “could”, “project”, “predict”, "project", “continue”, “plan”, “forecast” or other similar words or expressions. Forward-looking statements are based on certain assumptions, discuss future expectations, describe future plans and strategies, contain projections of results of operations or of financial condition or state other forward-looking information. The Company’s ability to predict results or the actual effect of future plans or strategies is limited. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, its actual results and performance may differ materially from those set forth in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and other factors that may cause the Company’s actual results in future periods to differ materially from forecasted results or stated expectations including the risks regarding Eurocastle’s ability to declare dividends or achieve its targets regarding asset disposals or asset performance.




1 In light of the Realisation Plan, the Adjusted NAV as at 30 June 2020 reflects additional reserves for future costs and potential liabilities, which have not been accounted for under the IFRS NAV. The IFRS NAV, as at 30 June 2020, is €30.5 million, or €16.45 per share.

2 Per share calculations for Eurocastle throughout this document are based on 1.9 million ordinary shares that were in issue throughout H1 2020.

3 Reflects corporate cash net of liabilities and additional reserves.

3 In light of the Realisation Plan, the Adjusted NAV as at 30 June 2020 reflects the additional reserves for future costs and potential liabilities of €17.0 million, which have not been accounted for under the IFRS NAV.

4 Amounts per share calculated on 1.9 million outstanding ordinary shares.


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation19.9.2020 16:25:00 CESTPress release

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone1 14+ months OS improvement was achieved in patients with lung or liver metastases, which are observed in 41% of postmenopausal women with HR+ aBC, and considered more aggressive and challenging to treat1-3 Data add to growing body of evidence for Piqray, the first and only treatment specifically approved for aBC with a PIK3CA mutation Basel, September 19, 2020 — Novartis today announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray® (alpelisib) in combination with fulvestrant, compared to fulvestrant alone, in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer patients with tumors harboring a PIK3CA mutation. Piqray is the only trea

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma19.9.2020 16:20:00 CESTPress release

Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma1-4 Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the COMBI-i clinical trial despite the study not meeting the primary endpoint for the investigational triplet therapy Spartalizumab development program continues, investigating the immunotherapy in combination with other anti-cancer agents Basel, September 19, 2020 — Novartis announced today detailed results from the Phase III COMBI-i trial evaluating the investigational immunotherapy spartalizumab (PDR001) in combination with the targeted therapies Tafinlar® (dabrafenib) and Mekinist® (trametinib) compared to Tafinlar + Mekinist alone1. The efficacy data achieved in the trial’s control arm among patients treated with Tafinlar + Mekinist represent the long

Roche presents new data from multiple Phase III studies of Tecentriq in triple-negative breast cancer at ESMO Virtual Congress 202019.9.2020 16:20:00 CESTPress release

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapyFinal overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours expressed PD-L1 and who received Tecentriq plus nab-paclitaxelResults from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel for the treatment of people with metastatic TNBC and whose tumours expressed PD-L1, did not meet its primary endpoint of progression-free survival Basel, 19 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical

Galapagos increases share capital through subscription right exercises18.9.2020 22:01:00 CESTPress release

Mechelen, Belgium; 18 September 2020, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 86,280 new ordinary shares on 18 September 2020, for a total capital increase (including issuance premium) of €2,403,087. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, CEO Onno van de Stolpe exercised 15,000 subscription rights. Three other management board members exercised an aggregate number of 15,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €353,435,739.72, the total number of securities conferring voting rights amounts to 65,340,842, which is also the tota

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-09-25 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-121061 SE00112819220.75 %1,000 +/- 2502032-06-01 1056 SE00045172902.25 %1,000 +/- 250 Settlement date 2020-09-29 Bids have to be entered by 10.00 on SEP 25, 2020 Highest permitted bid volume: 1 000 million in issue SGB 1061 and 1 000 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON SEP 25, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS18.9.2020 16:20:00 CESTPress release

Sveriges Riksbank CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS Bid procedure on 22 September 2020, Municipalities and Regions Bonds: Floating-Rate Notes (FRN) issued in SEK by Municipalities or Regions with maturity in 2025. The following issuers are accepted for delivery: Göteborgs KommunJönköpings KommunMalmö KommunNorrköpings Kommun Skåne Läns LandstingStockholms KommunSundsvalls KommunTäby KommunUppsala KommunVästerås KommunÖrebro KommunÖstersunds Kommun Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after 11 September 2020. Bids: Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se. Bid date: Tuesday 22 September 2020 Bid time: 1000-1100 hours (CEST) on the Bid date Requested volume: (corresponding nominal amount) SEK 750 +/- 750 million Highest permitted bid vol